Cary, North Carolina–based analytics stalwart SAS has launched SAS Clinical Acceleration, a cloud based software platform designed to help manage clinical trial data, analyze results and prepare regulatory submissions.
The modular system combines a content repository with a statistical computing environment so clinical development teams can manage, analyze, report and review clinical and medical data in a validated environment. The product is built on the SAS Viya platform.
SAS Clinical Acceleration is intended to support hybrid and decentralized trial designs and the growing use of real world, biomarker and digital data. The company says the software provides auditable actions, data traceability and repeatable analyses to help reduce delays and support regulatory compliance.
The system is aimed at both technical and nontechnical users, with no code and low code interfaces, open source integration, open data formats and the ability to run in different hosting environments. It is positioned as a single source of truth for regulated clinical trial operations to support collaboration among sponsors, contract research organizations and regulators.
Support for AI including large language models and digital twins and synthetic data with controls for transparency and explainability is baked in.
“Every day of delay in bringing a therapy to market can affect both costs and patient outcomes,” said Mark Lambrecht, global head of health care and life sciences at SAS. “With SAS Clinical Acceleration, we are working to shorten submission timelines and support collaboration across trials, phases and therapeutic areas.”
Case studies show large pharmas such as AstraZeneca using SAS Viya and SAS life sciences tools in their trial and approval processes.
SAS plans additional capabilities for the product, including workflow automation and expanded analytics features such as deeper integration of AI agents and copilots.
Filed Under: clinical trials, Drug Discovery, machine learning and AI
